LMNX Luminex Corporation

Luminex Corporation (NASDAQ:LMNX) today announced that it has settled the pending litigation with The Research Foundation for the State University of New York and the Board of Trustees of the University of Illinois (�Plaintiffs�). As part of the settlement, the Plaintiffs received a�one time�cash payment of $4.35�million with no admission of fault. The cash payment was made by Luminex in exchange for resolution of the dispute between the�parties and a complete release of all claims by the Plaintiffs against Luminex,�and, correspondingly a complete release of all claims by Luminex against�the Plaintiffs. The entire effect of the settlement payment will be reflected as a non-recurring item�in the first quarter financial results scheduled to be released on May 7, 2009. All other terms of the agreement are confidential. The parties intend to formally dismiss the lawsuit, as required by the Settlement Agreement.

About Luminex Corporation

Luminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the diagnostic and life sciences industries. The Company's xMAP� multiplex solutions include an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics research markets. The Company's xMAP technology is sold worldwide and is already in use in leading clinical laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex Corporation or xMAP technology can be obtained at www.luminexcorp.com.

Statements made in this release that express Luminex's or management's intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. The words "believe," "expect," "intend," "estimate," "anticipate," "will," "could," "should" and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company's actual results or performance could differ materially from those anticipated or projected in such forward-looking statements. Factors that could cause Luminex's actual results or performance to differ materially include risks and uncertainties relating to, among others, market demand and acceptance of Luminex's products, the Company's dependence on strategic partners for development, commercialization and distribution of products, concentration of the Company's revenue in a limited number of strategic partners, fluctuations in quarterly results due to a lengthy and unpredictable sales cycle and bulk purchases of consumables, Luminex's ability to scale manufacturing operations and manage operating expenses, gross margins and inventory levels, potential shortages of components, competition, the timing of regulatory approvals, the implementation, including any modification, of the Company's strategic operating plans, risks and uncertainties associated with implementing our acquisition strategy and the ability to integrate acquired companies or selected assets into our consolidated business operations, as well as the risks discussed under the heading "Risk Factors" in Luminex's Reports on Forms 10-K and 10-Q, as filed with the Securities and Exchange Commission. The forward-looking statements contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Luminex (NASDAQ:LMNX)
Historical Stock Chart
From Jun 2024 to Jul 2024

Luminex (NASDAQ:LMNX)
Historical Stock Chart
From Jul 2023 to Jul 2024